ImmuneBridge

At this year’s Innate Killer Summit, ImmuneBridge co-founder Jesse Cotari closed out his talk with a challenge to the field: Think like an NK cell. At ImmuneBridge, the inherent capabilities of NK cells inspires both what we make and how we operate: 📌We cultivate diversity—of thought, in our team, and by tapping into humanity’s rich immune heritage. 📌We engineer strategically, first harnessing NK cells’ innate potency and then modifying them in targeted contexts to amplify already-powerful cellular cures. 📌We embrace collaboration, by using NK cells’ ability to activate other cell types to orchestrate durable cancer cures—as well as by forging connections with like-minded companies. Thanks to Hanson Wade for inviting us to speak. Our Head of Research Nina Horowitz and VP of CMC Rui Tostoes also presented on optimal donor and recipient selection strategies and agile process development. It was a great opportunity to connect with our peers within the HSC-derived NK field (Adil Doganay Duru, Anna-Maria Georgoudaki, Erika von Euw, Ph.D., Hugh JM Brady, Jan Spanholtz), friends who appreciate the impact of donor selection (Martin Maiers and Sunil Acharya), and to continue to build links across the full spectrum of NK therapies (Evren Alici, Dan Kaufman, Tom Farrell, Andrew Houk). #InnateKillerSummit2024 #NKCelltherapy #CMC #celltherapy #aacr #immunotherapy

Our CSO Dr. Sumiti Jain was featured in a recent article by Aayushi Pratap in BioSpace discussing the immense potential of NK cells for making therapeutics that are potent, safe, scalable, and ultimately accessible to more patients.

Introducing Oliver Zill, VP of Computational Biology at ImmuneBridge We are thrilled to spotlight Oliver Zill, who leads ImmuneBridge’s Genomics and Data Platform initiatives. An industry veteran with over 20 years of experience in oncology, immunology, and genomics R&D, Oliver’s expertise is pivotal in propelling our capabilities to utilize high-dimensional data and computational algorithms for donor selection and cell therapy optimization. With previous roles at Genentech and Guardant Health, Oliver has led Computational Biology R&D groups and cross-functional product development teams for T-cell therapies, neoantigen vaccines, and circulating tumor DNA diagnostics. Most recently, he founded init.bio, a company that helps startups design and build computational platforms and teams for drug development. Oliver shares what drew him to ImmuneBridge: “I was captivated by ImmuneBridge’s mission to develop best-in-class allogeneic NK cell therapies—and that our approach flips the donor diversity ‘problem’ on its head. The data set we are generating provides a unique opportunity to employ modern techniques for high-dimensional data analysis and machine learning to make a major impact in immune cell therapies for cancer. Additionally, my graduate work involved leveraging inter-species variation to better understand gene regulation mechanisms, so ImmuneBridge’s strategy of leveraging genomic variation across individuals to identify the best candidates for cell therapies deeply resonated with me.“ Oliver's journey and vision are integral to our mission at ImmuneBridge, as we use computational approaches to characterize and harness humanity’s rich immune diversity to forge groundbreaking cancer therapies. #NKcelltherapy #Team #CompBio

ImmuneBridge Team Member Spotlight—Miguel Madero Meet Miguel Madero—ImmuneBridge’s VP of Software and Data Engineering, leading our Data Engineering and Tech initiatives. Miguel’s work is critical to enabling the data analytics that drive optimal donor selection for clinical manufacturing and to enhancing our models of the diverse ways NK cells interact with tumor cells. A seasoned entrepreneur and technologist with 25 years of experience building and leading teams, Miguel is an expert in driving process improvements at both large enterprises and startups. Most recently, he founded Foxtrot Health. We asked him—why ImmuneBridge? “I have always been mission-driven and I love what we're doing and its potential to save lives. It’s even better when being surrounded by super smart and passionate individuals that are fun to work with.” #NKcelltherapy #Team #SoftwareEngineering

ImmuneBridge Team Member Spotlight—Miguel Madero Meet Miguel Madero—ImmuneBridge’s VP of Software and Data Engineering, leading our Data Engineering and Tech initiatives. Miguel’s work is critical to enabling the data analytics that drive optimal donor selection for clinical manufacturing and to enhancing our models of the diverse ways NK cells interact with tumor cells. A seasoned entrepreneur and technologist with 25 years of experience building and leading teams, Miguel is an expert in driving process improvements at both large enterprises and startups. Most recently, he founded Foxtrot Health. We asked him—why ImmuneBridge? “I have always been mission-driven and I love what we're doing and its potential to save lives. It’s even better when being surrounded by super smart and passionate individuals that are fun to work with.” #NKcelltherapy #Team #SoftwareEngineering

A sneak peek from last week’s #photoshoot, featuring our lab and growing team. Big thanks to photographer Monica Semergiu, creative director Mollie McDowell, and Amy Puliafito for their help capturing the essence of our scientific work and the energy and electricity of the ImmuneBridge team and office. Much more to come. #NKcelltherapy #behindthescenes #wedoscience #celltherapy

At this year’s Innate Killer Summit, ImmuneBridge co-founder Jesse Cotari closed out his talk with a challenge to the field: Think like an NK cell. At ImmuneBridge, the inherent capabilities of NK cells inspires both what we make and how we operate: 📌We cultivate diversity—of thought, in our team, and by tapping into humanity’s rich immune heritage. 📌We engineer strategically, first harnessing NK cells’ innate potency and then modifying them in targeted contexts to amplify already-powerful cellular cures. 📌We embrace collaboration, by using NK cells’ ability to activate other cell types to orchestrate durable cancer cures—as well as by forging connections with like-minded companies. Thanks to Hanson Wade for inviting us to speak. Our Head of Research Nina Horowitz and VP of CMC Rui Tostoes also presented on optimal donor and recipient selection strategies and agile process development. It was a great opportunity to connect with our peers within the HSC-derived NK field (Adil Doganay Duru, Anna-Maria Georgoudaki, Erika von Euw, Ph.D., Hugh JM Brady, Jan Spanholtz), friends who appreciate the impact of donor selection (Martin Maiers and Sunil Acharya), and to continue to build links across the full spectrum of NK therapies (Evren Alici, Dan Kaufman, Tom Farrell, Andrew Houk). #InnateKillerSummit2024 #NKCelltherapy #CMC #celltherapy #aacr #immunotherapy

We're #hiring a new Lab Manager in San Francisco, California. Apply today or share this post with your network.

We're #hiring a Computational Biologist (contract). Apply today or share this post with your network!

We're #hiring a new Data Engineering & Lab Informatics Lead. Apply today or share this post with your network!